Helant (Omeprazole)

Helant (omeprazole) is indicated for a range of acid‑related gastrointestinal disorders in which reduction of gastric acid secretion helps promote healing and symptom relief, particularly in adult patients.

• Gastroesophageal reflux disease (GERD) to relieve heartburn and esophageal irritation.
• Healing of gastric and duodenal peptic ulcers.
• Prevention and treatment of NSAID‑induced gastric ulceration.
• Part of combination therapy for Helicobacter pylori eradication.
• Maintenance therapy to prevent recurrence of ulcer disease.

Side effects reported with Helant are generally mild, but some reactions may require medical attention.

Common

• Headache, mild dizziness, or feeling of light‑headedness that may affect daily activities.
• Upper abdominal discomfort, bloating, or flatulence that usually resolves without treatment.
• Nausea, occasional vomiting, or loss of appetite, often transient during the first weeks of therapy.
• Diarrhea or constipation occurring intermittently, which may improve with dietary adjustments.

Serious

• Severe allergic reaction such as rash, itching, swelling of face, lips, or tongue, requiring immediate medical care.
• Clostridioides difficile–associated colitis presenting with persistent diarrhea, which can be life‑threatening.
• Low magnesium levels (hypomagnesemia) leading to muscle cramps or irregular heartbeat, especially with long‑term use.
• Signs of liver injury including jaundice, dark urine, or abdominal pain, that should prompt discontinuation.

When prescribing or taking Helant, several precautionary measures should be considered to minimize risks and ensure safe use in various patient populations.

• Assess for known hypersensitivity to omeprazole or other proton‑pump inhibitors before initiation.
• Use the lowest effective dose for the shortest duration appropriate for the condition.
• Caution in patients with severe liver disease; dose adjustment may be required.
• Monitor serum magnesium during prolonged therapy, especially in the elderly.
• Evaluate the need for bone fracture risk assessment in long‑term users.
• Consider alternative therapy for patients with a history of gastric malignancy.

Helant may interact with other medicines, altering its effectiveness or increasing the risk of adverse effects.

Avoid

• Co‑administration with ketoconazole or itraconazole, which require acidic gastric pH for absorption.
• Concurrent use of clopidogrel, as omeprazole can reduce its antiplatelet activity.
• Simultaneous intake of atazanavir or nelfinavir, where reduced acidity may lower antiviral efficacy.

Use with caution

• Warfarin therapy, because omeprazole may enhance anticoagulant effect and increase INR.
• Digoxin, as altered gastric pH can affect its absorption and serum levels.
• Methotrexate, particularly high‑dose regimens, where reduced clearance may occur.